Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/sgHgBmzESK0/267273.php
Friday, 11 October 2013
Clinical trial examines oral supplementation in age-related macular degeneration
A daily 15 mg dose of the oral medication pazopanib for patients with age-related macular degeneration (AMD, a leading cause of blindness) resulted in improvements in vision and other measures related to the retina, according to a report of two clinical trials by Megan M. McLaughlin, M.S., of GlaxoSmithKline, King of Prussia, Pa., and colleagues. Most of the vision loss caused by AMD is connected to new blood vessel formation in the retina, according to the study background. Treatment with a drug that blocks new blood vessel formation is effective but must be given by injection in the eye...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment